Target Price | $326.40 |
Price | $293.72 |
Potential | 11.13% |
Number of Estimates | 30 |
30 Analysts have issued a price target Amgen 2026 . The average Amgen target price is $326.40. This is 11.13% higher than the current stock price. The highest price target is $420.00 42.99% , the lowest is $186.85 36.38% . | |
A rating was issued by 39 analysts: 21 Analysts recommend Amgen to buy, 15 to hold and 3 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Amgen stock has an average upside potential 2026 of 11.13% . Most analysts recommend the Amgen stock at Purchase. |
33 Analysts have issued a sales forecast Amgen 2025 . The average Amgen sales estimate is $36.1b . This is 3.35% higher than the revenue of the last 12 months(TTM). The highest sales forecast is $38.1b 9.21% , the lowest is $33.8b 3.08% .
This results in the following potential growth metrics:
2024 | $33.4b | 18.57% |
---|---|---|
2025 | $36.1b | 7.96% |
2026 | $36.7b | 1.70% |
2027 | $37.8b | 2.93% |
2028 | $38.2b | 1.10% |
2029 | $39.4b | 3.12% |
2030 | $41.1b | 4.30% |
2031 | $42.3b | 2.92% |
2032 | $43.2b | 2.15% |
34 Amgen Analysts have issued a net profit forecast 2025. The average Amgen net profit estimate is $11.5b . This is 73.13% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is $12.3b 85.97% , the lowest is $10.6b 60.19% .
This results in the following potential growth metrics and future Net Margins:
2024 | $4.1b | 39.11% |
---|---|---|
2025 | $11.5b | 180.18% |
2026 | $11.8b | 2.97% |
2027 | $12.4b | 4.76% |
2028 | $12.6b | 1.88% |
2029 | $13.1b | 4.19% |
2032 | $15.5b | 3.24% |
2024 | 12.24% | 48.64% |
---|---|---|
2025 | 31.76% | 159.55% |
2026 | 32.15% | 1.23% |
2027 | 32.72% | 1.77% |
2028 | 32.98% | 0.79% |
2029 | 33.32% | 1.03% |
2032 | 35.83% | 1.07% |
34 Analysts have issued a Amgen forecast for earnings per share. The average Amgen EPS is $21.30 . This is 74.16% higher than earnings per share in the financial year 2024. The highest EPS forecast is $22.88 87.08% , the lowest is $19.71 61.16% .
This results in the following potential growth metrics and future valuations:
2024 | $7.56 | 39.47% |
---|---|---|
2025 | $21.30 | 181.75% |
2026 | $21.93 | 2.96% |
2027 | $22.98 | 4.79% |
2028 | $23.41 | 1.87% |
2029 | $24.39 | 4.19% |
2030 | $25.79 | 5.74% |
2031 | $27.86 | 8.03% |
2032 | $28.76 | 3.23% |
Current | 24.18 | 56.51% |
---|---|---|
2025 | 13.89 | 42.56% |
2026 | 13.49 | 2.88% |
2027 | 12.87 | 4.60% |
2028 | 12.63 | 1.86% |
2029 | 12.12 | 4.04% |
2032 | 10.28 | 3.20% |
Based on analysts' sales estimates for 2025, the Amgen stock is valued at an EV/Sales of 5.75 and an P/S ratio of 4.41 .
This results in the following potential growth metrics and future valuations:
Current | 5.94 | 18.74% |
---|---|---|
2025 | 5.75 | 3.24% |
2026 | 5.65 | 1.67% |
2027 | 5.49 | 2.85% |
2028 | 5.43 | 1.14% |
2029 | 5.26 | 3.02% |
2032 | 4.80 | 2.10% |
Current | 4.56 | 18.33% |
---|---|---|
2025 | 4.41 | 3.24% |
2026 | 4.34 | 1.67% |
2027 | 4.22 | 2.85% |
2028 | 4.17 | 1.16% |
2029 | 4.04 | 3.02% |
2032 | 3.69 | 2.10% |
Analyst | Rating | Action | Date |
---|---|---|---|
Citigroup |
Neutral
➜
Neutral
|
Unchanged | Aug 06 2025 |
UBS |
Neutral
➜
Neutral
|
Unchanged | Aug 06 2025 |
Morgan Stanley |
Equal-Weight
➜
Equal-Weight
|
Unchanged | Aug 06 2025 |
B of A Securities |
Underperform
➜
Underperform
|
Unchanged | Jul 23 2025 |
Citigroup |
Neutral
➜
Neutral
|
Unchanged | Jul 22 2025 |
UBS |
Neutral
➜
Neutral
|
Unchanged | Jul 21 2025 |
Piper Sandler |
Overweight
➜
Overweight
|
Unchanged | Jun 27 2025 |
Analyst Rating | Date |
---|---|
Unchanged
Citigroup:
Neutral
➜
Neutral
|
Aug 06 2025 |
Unchanged
UBS:
Neutral
➜
Neutral
|
Aug 06 2025 |
Unchanged
Morgan Stanley:
Equal-Weight
➜
Equal-Weight
|
Aug 06 2025 |
Unchanged
B of A Securities:
Underperform
➜
Underperform
|
Jul 23 2025 |
Unchanged
Citigroup:
Neutral
➜
Neutral
|
Jul 22 2025 |
Unchanged
UBS:
Neutral
➜
Neutral
|
Jul 21 2025 |
Unchanged
Piper Sandler:
Overweight
➜
Overweight
|
Jun 27 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.